Lipella Pharmaceuticals announced an update on its ongoing multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus, OLP. The Company reported that three participants have completed the four-week treatment with LP-310, an oral rinse, with encouraging findings: The treatment was well tolerated and had no unpleasant taste.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIPO:
- Lipella Pharmaceuticals launches Oral Lichen Planus patient registry
- Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
- Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference
- Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
- Lipella Pharmaceuticals doses first two patients with LP-310